CD274 and non-small cell lung carcinoma: Other retrospective studies have focused on a further selected subgroup of patients with advanced NSCLC with PD-L1 TPS of at least 50% and ECOG PS scores of 2 treated with first-line pembrolizumab monotherapy.14,15,16 Results from the subgroup analysis in our cohort mirror the results reported from the largest study of such patients,14 which reported a median PFS and OS of 2.4 months and 3.0 months, respectively (eTable 3 in the Supplement).